Clinical Impact of Dual Time Point 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer
Authors:
- Takahiro EinamaTETakahiro Einama
- Yoji YamagishiYYYoji Yamagishi
- Yasuhiro TakihataYTYasuhiro Takihata
- Fukumi KonnoFKFukumi Konno
- Kazuki KobayashiKKKazuki Kobayashi
- Naoto YonamineNYNaoto Yonamine
- Ibuki FujinumaIFIbuki Fujinuma
- Takazumi TsunenariTTTakazumi Tsunenari
- Keita KouzuKKKeita Kouzu
- Akiko NakazawaANAkiko Nakazawa
- Toshimitsu IwasakiTIToshimitsu Iwasaki
- Eiji ShintoESEiji Shinto
Open Access
Abstract
We examined the value of preoperative dual time point (DTP) 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (FDG PET/CT) as a predictor of early recurrence or the outcomes in patients with pancreatic cancer. Standardized uptake values (SUVs) in DTP FDG PET/CT were performed as preoperative staging. SUVmax1 and SUVmax2 were obtained in 60 min and 120 min, respectively. ΔSUVmax% was defined as (SUVmax2 − SUVmax1)/SUVmax1 × 100. The optimal cut-off values for SUVmax parameters were selected based on tumor relapse within 1 year of surgery. Optimal cut-off values for SUVmax1 and ΔSUVmax% were 7.18 and 24.25, respectively. The combination of SUVmax1 and ΔSUVmax% showed higher specificity and sensitivity, and higher positive and negative predictive values for tumor relapse within 1 year than SUVmax1 alone. Relapse-free survival (RFS) was significantly worse in the subgroups of high SUVmax1 and high ΔSUVmax% (median 7.0 months) than in the other subgroups (p < 0.0001). The multivariate Cox analysis of RFS identified high SUVmax1 and high ΔSUVmax% as independent prognostic factors (p = 0.0060). DTP FDG PET/CT may effectively predict relapse in patients with pancreatic cancer. The combination of SUVmax1 and ΔSUVmax% identified early recurrent patient groups more precisely than SUVmax1 alone.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP 18K15295)
This publication has 27 references indexed in Scilit:
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)The Lancet, 2016
- Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancerAnnals of Nuclear Medicine, 2015
- Preoperative FDG-PET Predicts Early Recurrence and a Poor Prognosis After Resection of Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2014
- Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resectionInternational Journal of Clinical Oncology, 2010
- 18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing MorbidityAnnals of Surgery, 2008
- Role of positron emission tomography in decisions on treatment strategies for pancreatic cancerJournal of Hepato-Biliary-Pancreatic Surgery, 2006
- Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-EffectivenessAnnals of Surgery, 2005
- Detection of recurrent pancreatic cancer: Comparison of FDG-PET with CT/MRIPancreatology, 2005
- A PET study of 18 FDG uptake in soft tissue massesEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999